Purpose

The purpose of this study is to evaluate the effectiveness and safety of liraglutide/liraglutide + metformin in overweight/obese women with polycystic ovary syndrome (PCOS).

Methods

The related literatures published until April 2021 were searched in PubMed, Cochrane Library, MEDLINE and EmBase.

Results

Six randomized controlled trials of 127 related articles were obtained through searching. Three articles compared liraglutide with metformin, and four articles compared liraglutide combined with metformin with metformin. Our meta-analysis suggests that liraglutide was superior to metformin only in weight loss [MD = − 2.74, 95% CI (− 4.29, − 1.18), P = 0.0006]. Compared with metformin group, the combination group had significant advantages in weight loss [MD = − 3.81, 95% CI (− 5.16, − 2.46), P < 0.001], BMI [MD = − 2.59, 95% CI (− 3.12, − 2.07), P < 0.001], waist circumference [MD = − 6.26, 95% CI (− 7.79, − 4.72), P < 0.001], fasting blood glucose [MD = − 0.59, 95% CI (− 0.74, − 0.44), P < 0.001] and fasting insulin [MD = − 1.52, 95% CI (− 2.69, − 0.35), P = 0.01], while the incidence of adverse reactions was relatively high [RR = 2.91, 95% CI (1.55, 5.46), P = 0.00009].

Conclusion

The present results indicate that liraglutide and metformin have the similar effects in the treatment of overweight/obese PCOS patients. Liraglutide combined with metformin is more effective than metformin in improving PCOS, but it is necessary to master the correct medication method to reduce the occurrence of adverse reactions.

中文翻译：

---

利拉鲁肽治疗超重/肥胖多囊卵巢综合征患者的有效性和安全性：荟萃分析

目的

本研究的目的是评估利拉鲁肽/利拉鲁肽 + 二甲双胍对患有多囊卵巢综合征 (PCOS) 的超重/肥胖女性的有效性和安全性。

方法

在 PubMed、Cochrane Library、MEDLINE 和 EmBase 中检索了截至 2021 年 4 月发表的相关文献。

结果

通过检索获得127篇相关文章的6项随机对照试验。三篇文章比较了利拉鲁肽和二甲双胍，四篇文章比较了利拉鲁肽联合二甲双胍和二甲双胍。我们的荟萃分析表明，利拉鲁肽仅在减肥方面优于二甲双胍[MD = - 2.74, 95% CI (- 4.29, - 1.18), P  = 0.0006]。与二甲双胍组相比，联合组在减肥[MD = - 3.81, 95% CI (- 5.16, - 2.46), P  < 0.001]、BMI [MD = - 2.59, 95% CI (- 3.12, − 2.07), P  < 0.001], 腰围 [MD = − 6.26, 95% CI (− 7.79, − 4.72), P  < 0.001], 空腹血糖 [MD = − 0.59, 95% CI (− 0.74, − 0.44), P < 0.001]和空腹胰岛素[MD = - 1.52, 95% CI (- 2.69, - 0.35), P  = 0.01]，而不良反应发生率相对较高[RR = 2.91, 95% CI (1.55, 5.46) , P  = 0.00009]。

结论

目前的结果表明，利拉鲁肽和二甲双胍在治疗超重/肥胖 PCOS 患者中具有相似的效果。利拉鲁肽联合二甲双胍改善PCOS的效果优于二甲双胍，但需要掌握正确的用药方法，减少不良反应的发生。